Cancer immune therapy for myeloid malignancies: present and future

Medicin og biovidenskab

• Acute Myeloid Leukemia 32%
• Arginase 44%
• Blocking Antibodies 41%
• Bone Marrow 25%
• Calreticulin 48%
• Chimeric Antigen Receptors 46%
• Clinical Trials 22%
• Cytokines 21%
• Epitopes 29%
• Exons 28%
• Gene Expression Regulation 37%
• Hematopoietic Stem Cells 34%
• Immune System 27%
• Ligands 24%
• Mutation 19%
• Myelodysplastic Syndromes 38%
• Myeloid Progenitor Cells 46%
• Neoplasm Antigens 36%
• Neoplasms 100%
• Phenotype 20%
• Proteins 12%
• T-Lymphocytes 21%
• Therapeutics 50%
• Vaccination 82%